Pliant Therapeutics announced it will present data from its ongoing Phase 1b trial of PLN-101095, a dual integrin inhibitor combined with pembrolizumab, at the European Society for Medical Oncology Congress 2026. The trial, named FORTIFY, targets patients with immune checkpoint inhibitor-refractory advanced solid tumors, including non-small cell lung cancer and renal cell carcinoma. This presentation highlights Pliant's progress in developing treatments for cancers resistant to current immunotherapies. The company continues enrolling patients and advancing clinical research to evaluate safety and antitumor activity.
Pliant Therapeutics' upcoming presentation at the European Society for Medical Oncology Congress 2026 is the subject. For readers following the health sector, here is Pluang's market snapshot as of Oct 20, 2026 03:02 WIB: Of 150 priced US health stocks, 87 rose and 62 fell. Notable movers include TNGX at USD 23.60 with a +7.08% change and a typical hold time of 5 days, ABCL at USD 11.80 down -6.94% with 100% sell order activity and a 41-day hold time, and SMMT at USD 15.60 up +6.63% with balanced buy/sell orders and a 17-day hold time.
Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...
The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...
W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...
GE Aerospace is set to report its Q3 earnings with analysts forecasting a 21.7% rise in earnings per share to $2.02 and nearly 12% revenue growth to about $12.7 billion. Despite consistently beating estimates, the stock has fallen after past reports ...
Silence Therapeutics' stock surged 125.6% to $19.58 following Merck KGaA's agreement to acquire the RNA-interference drug developer for about $1.3 billion in equity value. Merck will pay $20 per share, a 130% premium over the recent closing price. Ot...
